CBINSIGHTS-医疗健康2021第一季度投融资状况报告（英文）-2021.4-75页_6mb

State Of Healthcare Q1'21 Report: Investment & Sector Trends To Watch

Core Content

The State of Healthcare Q1'21 Report provides an overview of the global healthcare investment landscape, highlighting key trends and developments across various sectors. It covers funding figures, deal counts, M&A activity, and innovations in digital health, AI, telehealth, mental health, women's health, and other critical areas.

Main Trends and Key Information

Overall Healthcare Funding

• Global healthcare funding hit a new quarterly record in Q1'21 with $31.6B in equity funding.
• Deal count increased by 9% to 1,500+ deals, the second-highest in the last 12 quarters.
• Asia saw a 12% decline in funding QoQ, while North America and Europe experienced growth, with North America seeing over 2x growth in mega-rounds (100M+ deals).

Digital Health

• Digital health funding reached an all-time high of $9B in Q1'21, with a 9% increase in deal count.
• Early-stage deals saw a slight uptick, while mid-stage remained consistent and late-stage declined by 1%.

AI in Healthcare

• AI funding reached $2.5B in Q1'21, a new record.
• Deal count increased by 9% to 111, with major investments in AI-driven drug discovery, diagnostics, and patient engagement.
• Key players include Insitro, Cedar, Valo, Strive Health, and K Health, all leveraging AI and machine learning.

Telehealth

• Global telehealth funding reached $4.2B, a record high, with 130+ deals from 32 countries.
• Six telehealth companies became unicorns (1B+ valuations).
• Deal count increased by 10% QoQ, showing continued interest in the sector.

Women's Health

• Funding reached $964M, largely driven by Ro's $500M round.
• Nearly 70% of deals in Q1'21 were early-stage, indicating strong innovation in the sector.
• Regulatory updates and product launches suggest growing interest in women's health solutions.

Mental Health

• Funding increased by 54% QoQ to $852M, with a 14% rise in deal count.
• Late-stage mental health and wellness platforms targeting the employer market drove this growth.

Medical Devices

• Funding reached $4.6B, a 23% decline from Q4'20's peak.
• Deal count fell by 11% QoQ, but mega-rounds in digital pathology and point-of-care testing (POCT) contributed to the quarter's funding.

Health IT

• Funding doubled YoY to $1.8B, with 52 deals.
• Early-stage deals dropped to 7% of total deal share, while mid- and late-stage funding remained significant.

Mergers & Acquisitions

• Healthcare incumbents like UnitedHealth Group and Cigna made significant M&A moves.
• Key acquisitions include:
  • Appress Health acquired PatientPing for care coordination.
  • Cigna acquired MDLIVE for telehealth.
  • Nuance Communications acquired Saykara for AI clinical documentation.
  • UnitedHealth Group acquired Change Healthcare for $13B.
• Digital health M&A spanned 32 countries, with notable deals in the U.S., U.K., India, and others.

Big Tech in Healthcare

• Microsoft:
  • Acquired Nuance Communications for $19.7B.
  • Launched Microsoft Vaccination Management and partnered with UCB for drug discovery.
• Google:
  • Expanded Care Studio, a healthcare EHR tool.
  • Partnered with Boehringer Ingelheim for quantum computing in drug R&D.
  • Invested in Insitro and Verily Life Sciences.
• Amazon:
  • Expanded Amazon Care services and received emergency use authorization for Covid-19 tests.

Consumer Digital Health Companies

• Several consumer-focused digital health companies announced SPACs, including Talkspace, 23andMe, Sharecare, Owlet, and DocGo.
• These SPACs reflect growing interest in telehealth, genomics, and remote patient monitoring.

Top Unicorns in Q1'21

• PointClickCare, Cedar, Hinge Health, Atai Life Sciences, and Aledade were the top unicorns.
• These companies are valued at $4B, $3.2B, $3B, $2B, and $1.9B, respectively.

Sector Highlights

AI

• Companies using AI to develop healthcare products or provide SaaS solutions.
• Focus areas include drug discovery, clinical data analysis, and patient engagement.

Women's Health

• Companies providing healthcare products and services tailored to women.
• Includes telehealth, digital therapeutics, and personalized care solutions.

Telehealth

• Companies using technology to deliver clinical services remotely.
• Includes virtual care platforms, online pharmacy services, and in-home care solutions.

Omics

• Companies involved in genomic, transcriptomic, proteomic, and metabolomic data.
• Despite a 12% decline in funding, the sector continues to receive mid- and late-stage investments.

Medical Devices

• Companies developing devices for diagnosis, treatment, and monitoring.
• Includes remote patient monitoring, point-of-care testing, and digital pathology.

Health IT

• Companies providing software solutions to healthcare providers.
• Focus on interoperability, data analytics, and clinical integration.

Mental Health

• Companies applying technology to emotional, psychological, and social well-being.
• Includes telebehavioral health, AI-driven diagnostics, and wellness platforms.

Conclusion

The Q1'21 report highlights a shift in focus from the immediate effects of the Covid-19 pandemic to long-term transformation in healthcare. Digital health, AI, and telehealth are leading the charge, with significant funding and M&A activity. Consumer-centric solutions, big tech partnerships, and innovations in data analytics are also shaping the future of the industry.